HCW Biologics Inc.

Contributing Author

Recent Articles by HCW Biologics Inc.

May-27	HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen HCWB -25.95% GlobeNewswire
May-21	HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules HCWB +6.17% GlobeNewswire
May-14	HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results HCWB +262.02% HCWB GlobeNewswire
May-14	HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies HCWB GlobeNewswire
Apr-30	HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum HCWB +15.63% GlobeNewswire
Apr-27	HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors HCWB +16.88% GlobeNewswire
Mar-31	HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results HCWB -16.67% HCWB GlobeNewswire
Mar-17	HCW Biologics Closes Exclusive Worldwide License for HCW11-006 - A High Potential Fusion Immunotherapeutic HCWB -6.33% GlobeNewswire
Mar-16	HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances HCWB +81.19% GlobeNewswire
Mar-02	HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter HCWB GlobeNewswire
Feb-17	HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules HCWB GlobeNewswire
Feb-13	HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune HCWB -21.23% GlobeNewswire
Nov-19	HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules HCWB -17.01% GlobeNewswire
Nov-18	HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease HCWB -21.24% GlobeNewswire
Nov-14	HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results HCWB +20.48% GlobeNewswire
Nov-10	HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer HCWB GlobeNewswire
Nov-07	HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting HCWB -9.04% GlobeNewswire
Oct-22	HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment HCWB GlobeNewswire
Oct-16	HCW Biologics to Participate in the 2025 Maxim Growth Summit HCWB -7.37% GlobeNewswire
Oct-16	HCW Biologics' Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer HCWB -7.37% GlobeNewswire
Sep-30	HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment About its Proprietary T-Cell Engager Program HCWB GlobeNewswire
Sep-18	HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing HCWB +5.34% GlobeNewswire
Sep-16	HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development HCWB -15.31% GlobeNewswire
Sep-09	HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program HCWB -6.82% GlobeNewswire
Aug-25	HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market HCWB +60.82% GlobeNewswire
Aug-18	HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results HCWB -11.44% HCWB GlobeNewswire
Jun-27	HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors HCWB +6.64% GlobeNewswire
Jun-26	HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements HCWB -5.17% GlobeNewswire
Jun-04	HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech HCWB -8.36% GlobeNewswire
May-15	HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results HCWB +9.15% HCWB -6.92% GlobeNewswire
May-13	HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules HCWB -12.34% GlobeNewswire
May-13	HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization HCWB +92.90% GlobeNewswire

HCW Biologics Inc.

Recent Articles by HCW Biologics Inc.

Upgrade your Finviz experience